Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99

Fig. 1

Comparison of baseline ECDHER2 values as detected in plasma (n = 47) or serum (n = 13) in two SAKK studies. Median values of plasma ECDHER2 levels of selected postmenopausal patients with ER positive tumors (left) compared to the one detected in serum of patients entering the SAKK23/04 (in both studies median: 21 ng/ml; P = 0.42)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us